Evidence map›Paper›PMID 33949711›Full record

Trial reportThe Prostate2021

The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.

Jen-Tsan Chi, Pao-Hwa Lin, Vladimir Tolstikov, Taofik Oyekunle, Gloria C G Alvarado, Adela Ramirez-Torres, Emily Y Chen, Valerie Bussberg, Bo Chi, Bennett Greenwood and 4 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Prostate, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jen-Tsan ChiDepartment of Molecular Genetics and Microbiology, Center for Genomics and Computational Biology, Duke University Medical Center, Durham, North Carolina, USA.ORCID 0000-0003-3433-903X
Pao-Hwa LinDivision of Nephrology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Vladimir TolstikovBERG, Framingham, Massachusetts, USA.
Taofik OyekunleDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Gloria C G AlvaradoCenter for Integrated Research in Cancer and Lifestyle, Cedars-Sinai, Los Angeles, California, USA.
Adela Ramirez-TorresCenter for Integrated Research in Cancer and Lifestyle, Cedars-Sinai, Los Angeles, California, USA.
Emily Y ChenBERG, Framingham, Massachusetts, USA.
Valerie BussbergBERG, Framingham, Massachusetts, USA.
Bo ChiDepartment of Molecular Genetics and Microbiology, Center for Genomics and Computational Biology, Duke University Medical Center, Durham, North Carolina, USA.
Bennett GreenwoodBERG, Framingham, Massachusetts, USA.
Rangaprasad SarangarajanBERG, Framingham, Massachusetts, USA.
Niven R NarainBERG, Framingham, Massachusetts, USA.
Michael A KiebishBERG, Framingham, Massachusetts, USA.
Stephen J FreedlandCenter for Integrated Research in Cancer and Lifestyle, Cedars-Sinai, Los Angeles, California, USA.ORCID 0000-0002-8104-6419
Framingham State University · USCedars-Sinai Medical Center · USDuke University · USDuke Medical Center · US

Funding

Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653
6 · The paper itself

Abstract

backgroundProstate cancer (PC) is the second most lethal cancer for men. For metastatic PC, standard first-line treatment is androgen deprivation therapy (ADT). While effective, ADT has many metabolic side effects. Previously, we found in serum metabolome analysis that ADT reduced androsterone sulfate, 3-hydroxybutyric acid, acyl-carnitines but increased serum glucose. Since ADT reduced ketogenesis, we speculate that low-carbohydrate diets (LCD) may reverse many ADT-induced metabolic abnormalities in animals and humans.

methodsIn a multicenter trial of patients with PC initiating ADT randomized to no diet change (control) or LCD, we previously showed that LCD intervention led to significant weight loss, reduced fat mass, improved insulin resistance, and lipid profiles. To determine whether and how LCD affects ADT-induced metabolic changes, we analyzed serum metabolites after 3-, and 6-months of ADT on LCD versus control.

resultsWe found androsterone sulfate was most consistently reduced by ADT and was slightly further reduced in the LCD arm. Contrastingly, LCD intervention increased 3-hydroxybutyric acid and various acyl-carnitines, counteracting their reduction during ADT. LCD also reversed the ADT-reduced lactic acid, alanine, and S-adenosyl methionine (SAM), elevating glycolysis metabolites and alanine. While the degree of androsterone reduction by ADT was strongly correlated with glucose and indole-3-carboxaldehyde, LCD disrupted such correlations.

conclusionsTogether, LCD intervention significantly reversed many ADT-induced metabolic changes while slightly enhancing androgen reduction. Future research is needed to confirm these findings and determine whether LCD can mitigate ADT-linked comorbidities and possibly delaying disease progression by further lowering androgens.

Indexed as

AgedAndrogen AntagonistsAndrosteroneAntineoplastic Agents, HormonalDiet, Carbohydrate-RestrictedHumansMaleMetabolomicsMiddle AgedProstatic NeoplasmsAndrogen AntagonistsAndrosteroneandrosterone sulfateAntineoplastic Agents, Hormonal3-formyl indole3-hydroxybutyric acidADTandrogen sulfateindole-3-carboxaldehydeketogenesislow carbohydrate dietmetabolomicsprostate cancer

Identifiers

PMID33949711
PMCPMC8167376
OpenAlexW3158618564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.